Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Medtronic
Cantor Fitzgerald
Citi
Merck
Daiichi Sankyo
Farmers Insurance
Deloitte
Queensland Health
Teva

Generated: April 25, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 018905

« Back to Dashboard

NDA 018905 describes HEXABRIX, which is a drug marketed by Guerbet and is included in one NDA. Additional details are available on the HEXABRIX profile page.

The generic ingredient in HEXABRIX is ioxaglate meglumine; ioxaglate sodium. Additional details are available on the ioxaglate meglumine; ioxaglate sodium profile page.
Summary for 018905
Tradename:HEXABRIX
Applicant:Guerbet
Ingredient:ioxaglate meglumine; ioxaglate sodium
Patents:0
Formulation / Manufacturing:see details

Profile for product number 002

Active Rx/OTC/Discontinued:DISCNDosage:INJECTABLE;INJECTIONStrength39.3%;19.6%
Approval Date:Jul 26, 1985TE:RLD:No

Expired US Patents for NDA 018905

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 ➤ Try a Free Trial ➤ Try a Free Trial
Guerbet HEXABRIX ioxaglate meglumine; ioxaglate sodium INJECTABLE;INJECTION 018905-002 Jul 26, 1985 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

UBS
US Department of Justice
Daiichi Sankyo
Johnson and Johnson
Citi
Farmers Insurance
Fish and Richardson
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.